

January 31, 2025

## Malik Lifesciences Private Limited: Update on material Event

### Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Short-term – non-fund based working capital limits	15.00	15.00	[ICRA]A1+; outstanding
Long-term/Short-term – fund based/non-fund based limits	62.00	62.00	[ICRA]AA(Stable)/ [ICRA]A1+; outstanding
Unallocated limits	14.00	14.00	[ICRA]AA(Stable)/ [ICRA]A1+; outstanding
<b>Total</b>	<b>91.00</b>	<b>91.00</b>	

\*Instrument details are provided in Annexure-I

### Rationale

### Material Event

On January 22, 2025, and January 23, 2025, Akums Drugs & Pharmaceuticals Limited (ADPL) informed the stock exchanges regarding searches initiated by the Income Tax (IT) department at few offices and manufacturing units of the company, its subsidiaries and the residences of few of its employees/key managerial personnel from January 15, 2025, till 11:00 pm on January 21, 2025. As per the company's exchange disclosure, it has not yet received any written communication from the IT department regarding the outcome of the search.

### Impact of Material Event

Based on ADPL's disclosures and discussions with the management, ICRA understands that the business and operations of the company continued without any disruptions except some minor operational hiccups. Moreover, there have been no demands which have been raised on the company as of date. ICRA also notes that the company's liquidity position continues to remain adequate with minimal utilisation of working capital limits and there has been no impact on the availability of bank funding. ICRA would continue to monitor closely, any such developments related to this event and take appropriate rating action, if necessary.

Please refer to the following link for the previous detailed rationale that captures the key financial indicators, key rating drivers and their description, liquidity position, rating sensitivities: [click here](#)

### Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	<a href="#">Corporate Credit Rating Methodology Pharmaceuticals</a>
Parent/Group support	Not applicable
Consolidation/Standalone	ICRA has taken a consolidated view of ADPL and its subsidiaries, PCHPL, MLPL and MNL, while assigning the credit ratings, given the common management and significant operational and financial linkages among the entities. For arriving at the ratings, ICRA has considered the consolidated financials of ADPL. As on March 31, 2024, the company had 14 subsidiaries and one step-down subsidiary, which are all enlisted in Annexure II.

## About the company

Incorporated in 2004, Malik Lifesciences Private Limited was established to manufacture fragrance products from a manufacturing facility in Haridwar (Uttarakhand) that enjoyed excise duty exemption till March 2020. In September 2013, the company was acquired by ADPL, thus becoming a 100% subsidiary of the latter. Following the acquisition, the management of ADPL shifted the manufacturing facility of MLPL to a separate plot of land and set up units compliant with various international manufacturing practices. The upgraded plant commenced commercial production from November 2014. The company has the capacities to manufacture oral solid dosage forms for penicillin and cephalosporin, steroids and cycotoxins.

Incorporated in 2004, ADPL is a leading contract manufacturer of formulations for domestic as well as multinational pharmaceutical and wellness companies in India. ADPL has 12 manufacturing facilities in Uttarakhand and Himachal Pradesh for its formulations manufacturing business and three manufacturing units in Punjab and Haryana for its API manufacturing business. These manufacturing units are housed under ADPL and its various subsidiaries. The Group has commercialised more than 4,000 formulations across more than 60 dosage forms.

In FY2020, the company raised Rs. 500 crore from Quadria Capital in exchange for a 15.09% stake, of which Rs. 320.0 crore was infused into the company and the balance was paid to the promoters against sale of shares. Subsequently, ADPL came out with an IPO in August 2024.

## Status of non-cooperation with previous CRA: Not applicable

## Any other information: None

## Rating history for past three years

Current (FY2025)				Chronology of rating history for the past 3 years							
Instrument	Type	Amount Rated (Rs Crore)	Jan 31, 2025	FY2025		FY2024		FY2023		FY2022	
				Date	Rating	Date	Rating	Date	Rating	Date	Rating
<b>Unallocated Limits</b>	Long term/ Short term	14.00	[ICRA]AA (Stable)/ [ICRA]A1+	09-OCT-2024	[ICRA]AA (Stable)/ [ICRA]A1+	-	-	-	-	-	-
<b>Non-fund based working capital limits</b>	Short term	15.00	[ICRA]A1+	09-OCT-2024	[ICRA]A1+	08-SEP-2023	[ICRA]A1+	30-JUN-2022	[ICRA]A1+	09-JUN-2021	[ICRA]A1+
<b>Fund-based/ non-fund based working capital limits</b>	Long term/ Short term	62.00	[ICRA]AA (Stable)/ [ICRA]A1+	09-OCT-2024	[ICRA]AA (Stable)/ [ICRA]A1+	08-SEP-2023	[ICRA]AA-(Stable)/ [ICRA]A1+	30-JUN-2022	[ICRA]AA-(Stable)/ [ICRA]A1+	09-JUN-2021	[ICRA]AA-(Stable)/ [ICRA]A1+
<b>Fund-based working capital limits</b>	-	-	-	-	-	08-SEP-2023	[ICRA]AA-(Stable)	30-JUN-2022	[ICRA]AA-(Stable)	09-JUN-2021	[ICRA]AA-(Stable)

## Complexity level of the rated instruments

Instrument	Complexity Indicator
Non-fund based working capital limits	Very simple
Long-term short-term fund based/ non fund based working capital limits	Simple
Long-term short-term - Unallocated limits	NA

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

**Annexure I: Instrument details**

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Non-fund based limits	NA	NA	NA	15.00	[ICRA]A1+
NA	Fund based /non-fund based limits	NA	NA	NA	62.00	[ICRA]AA(Stable)/ [ICRA]A1+
NA	Unallocated limits	NA	NA	NA	14.00	[ICRA]AA(Stable)/ [ICRA]A1+

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

**Annexure II: List of entities considered for consolidated analysis**

Company Name	ADPL's Ownership	Consolidation Approach
<b>SUBSIDIARIES</b>		
Akumentis Healthcare Limited	91.49%	Full Consolidation
Qualymed Pharma Private Limited	100%	Full Consolidation
Akums Healthcare Limited	100%	Full Consolidation
Burroughs Welcome Pharmacia Private Limited*	99.93%	Full Consolidation
Amazing Research Laboratories Ltd*	100%	Full Consolidation
Malik Lifesciences (P) Ltd	100%	Full Consolidation
Maxcure Nutravedics Ltd	100%	Full Consolidation
May & Baker Pharmaceuticals Ltd*	100%	Full Consolidation
Nicholas Healthcare Ltd	100%	Full Consolidation
Plenteous Pharmaceuticals Ltd	100%	Full Consolidation
Pure & Cure Healthcare Private Limited	100%	Full Consolidation
Unosource Pharma Ltd	100%	Full Consolidation
Upadrish Reserchem LLP	99.93%	Full Consolidation
Sarvagonaushdhi Private Limited	100%	Full Consolidation
<b>STEP DOWN SUBSIDIARIES</b>		
Medibox Pharma Private Limited	100%	Full Consolidation

Source: ADPL Q1 FY2025 results

Note: ICRA has taken a consolidated view of Akums Drugs & Pharmaceuticals Limited and its subsidiaries – Pure & Cure Healthcare Private Limited, Malik Lifesciences Private Limited and Maxcure Nutravedics Limited.

\*Hived off on April 1, 2024

## ANALYST CONTACTS

**Shamsher Dewan**  
+91 124 4545328  
[shamsherd@icraindia.com](mailto:shamsherd@icraindia.com)

**Deepak Jotwani**  
+91 124 4545328  
[deepak.jotwani@icraindia.com](mailto:deepak.jotwani@icraindia.com)

**Kinjal Shah**  
+91 022 61143400  
[kinjal.shah@icraindia.com](mailto:kinjal.shah@icraindia.com)

**Gaurav Kushwaha**  
+91 22 61143465  
[gaurav.kushwaha@icraindia.com](mailto:gaurav.kushwaha@icraindia.com)

## RELATIONSHIP CONTACT

**L. Shivakumar**  
+91 22 6114 3406  
[shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**  
Tel: +91 124 4545 860  
[communications@icraindia.com](mailto:communications@icraindia.com)

## HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

[info@icraindia.com](mailto:info@icraindia.com)

## ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited



### Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



### Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.